Get started

More results...

Filter by Content types

Alerts LATEST ALERTS

  • Bangladesh Youth call on government to implement stricter tobacco laws ...
  • India High Court puts enforcement against chewing tobacco on hold ...
  • Taiwan Four companies withdraw from HTP review process ...
  • Italy Agricultural organisation urges balanced approach to TED revision ...
  • Saudi Arabia ZATCA sends reminder to file tax returns ...
  • India South Goa officials prosecute shops selling tobacco too close to schools ...
  • Ohio - United States Court rules local governments can set laws, including bans, on flavoured tobacco ...
  • New Hampshire - United States Bill expanding definition of ‘tobacco product’ heads to governor ...
  • Taiwan Proposal to eliminate licence requirements for tobacco distribution and sales ...
  • Bulgaria Tobacco Act amendment officially published ...
  • Iraq Parliament due to vote on bills affecting vapes and tobacco ...
  • Greece Ministry updated notified tobacco product list ...
News analysis

US FDA debuts AI tool ahead of time but early users encounter teething problems

Written by || 19th June 2025 || News analysis | Health and science | Marketing and retailing | Technology and innovation | GeographiesNorth America United States

With great fanfare, the US Food and Drug Administration (FDA) on 2nd June 2025 announced the agency-wide rollout of its new artificial intelligence (AI) scientific review assistant, Elsa. The launch, FDA commissioner Marty Makary proudly explained, took place almost a month ahead of schedule, with the tool having already proven helpful in significantly streamlining staff workflows.

However, mixed feedback on its results has raised questions about the tool’s readiness and performance capabilities.

Contact a sales agent
I'm already a subscriber
Author default picture

TobaccoIntelligence

This article was written by one of TobaccoIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual nicotine markets.

Our Key Benefits

The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.